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A B S T R A C T
Objective: To assess the effectiveness of 10-valent pneumococcal conjugate vaccine (PCV10) against
invasive pneumococcal disease (IPD) due to vaccine serotypes of Streptococcus pneumoniae post
introduction of the vaccine into the routine immunization program in Pakistan.
Methods: A matched case–control study was conducted at 16 hospitals in Sindh Province, Pakistan.
Children aged <5 years (eligible to receive PCV10) who presented with radiographically confirmed
pneumonia and/or meningitis were enrolled as cases. PCR for the lytA gene was conducted on blood (for
radiographic pneumonia) and cerebrospinal fluid (for meningitis) samples to detect S. pneumoniae. The
proportion of IPD due to vaccine serotypes (including vaccine-related serogroups) was determined
through serial multiplex PCR. For each case, at least five controls were enrolled from children hospitalized
at the same institution, matched for age, district, and season.
Results: Of 92 IPD patients enrolled during July 2013 to March 2017, 24 (26.0%) had disease caused by
vaccine serotypes. Most case (87.5% of 24) and control (66.4% of 134) children had not received any PCV10
doses. The estimated effectiveness of PCV10 against vaccine-type IPD was 72.7% (95% confidence interval
(CI) 7.2% to 92.6%) with at least one dose, 78.8% (95% CI 11.9% to 96.0%) for at least two doses, and 81.9%
(95% CI 55.7% to 97.9%) for all three doses of vaccine.
Conclusions: The vaccine effectiveness point estimates for PCV10 were high and increased with increasing
number of doses. However, vaccine effectiveness estimates did not reach statistical significance, possibly
due to low power. The findings indicate the likely impact of vaccine in reducing the burden of vaccine-
type IPD if vaccine uptake can be improved.
© 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Pneumococcal disease is a major cause of childhood morbidity
and mortality worldwide (O’Brien et al., 2009). A significant
proportion of pneumonia and meningitis in low and middle-
income settings is attributed to Streptococcus pneumoniae, often
presenting as invasive pneumococcal disease (IPD) (O’Brien et al.,
2009; Zar et al., 2013). The pneumococcal conjugate vaccine (PCV)
has contributed significantly in reducing vaccine-related child-
hood morbidity and mortality in the developed world (Hsu et al.,
2009; Loo et al., 2014). Several middle- to low-income countries
have introduced PCV into their routine immunization schedules
with the assistance of Gavi—The Vaccine Alliance (IVAC, 2014).
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There are, however, few reports on post-vaccine
introduction assessment available from these countries, espe-
cially those in Asia. Pakistan was the first country in South Asia
to introduce the 10-valent PCV (PCV10) into its national
expanded program on immunization (EPI). A scientific assess-
ment of vaccine effectiveness could help policymakers under-
stand the performance of a routine vaccination program in
Pakistan and provide information to guide decisions on
introducing or sustaining PCV programs in other countries in
the region. The primary objective of this study was to assess the
effectiveness of PCV10 on IPD due to vaccine serotypes of S.
pneumoniae. This appears to be the first such evaluation of any
pneumococcal vaccine in the region.
Methods
Setting
Pakistan is a lower middle-income country with a population
of more than 200 million (Pakistan Bureau of Statistics, 2017) and
a gross domestic product (GDP) per capita of US$ 1468.20 (World
Bank, 2019). Globally, Pakistan has the third highest burden of
child mortality, and progress towards reducing child mortality
has been slow (Bhutta et al., 2013). Infectious diseases,
particularly vaccine-preventable illnesses, contribute a signifi-
cant burden to childhood mortality, with Pakistan identified as
one of the six countries globally with a high burden of S.
pneumoniae-related mortality (WHO, 2000). Sentinel site surveil-
lance has been established at several public and private secondary
and tertiary care hospitals serving low and middle-income
populations in eight districts of the province of Sindh. Sindh is
the second most populous province in Pakistan, with a population
of 48 million.
PCV10 was introduced into the Sindh EPI on April 1, 2013, with a
schedule of three doses given at 6, 10, and 14 weeks of age and no
opportunity for catch-up vaccination (Ali et al., 2016). All vaccines
are provided free of cost to children of eligible age through
designated government EPI centers and outreach facilities.
Twenty-nine percent of children in Sindh were reported to be
fully vaccinated before the initiation of this study (Pakistan
Demographic and Health Survey, 2013).
Sixteen healthcare facilities (nine public and seven private)
were included in the study. These sites were established based on
the availability of pediatric inpatient care, including the diagnosis,
treatment, and management of childhood pneumonia and
meningitis, the availability of chest radiography facilities, and
the willingness of the hospital administration to participate in the
study. A list of participating hospitals by district is provided in the
Supplementary material (Appendix S1).
Study design and enrollment
A matched case–control study design was used. Case enroll-
ment began in July 2013 and was concluded in March 2017.
Children admitted to inpatient units at the sentinel hospitals were
screened for eligibility prior to enrollment in the study. A research
team (comprising a medical officer and/or nurse) at each sentinel
site maintained inpatient lists and assessed each individual child’s
eligibility for enrollment.
Children born on or after February 15, 2013 (who would
have been eligible to receive at least one dose of PCV10) and
who were less than 5 years of age at the time of the study, who
had a provisional diagnosis of pneumonia and/or meningitis,
and who were residents of study catchment districts were
screened for enrollment as a case patient. Children were
considered to have suspected severe pneumonia if they
presented with signs of fast respiratory rate (>60 breaths per
minute for children younger than 2 months, >50 per minute for
those aged 2–11 months, and >40 per minute for those aged 12–
59 months), fever (>38.3 C), and at least one of three danger
signs, including lower chest wall indrawing, central cyanosis,
and inability to drink (Scott et al., 2012). Similarly, children
were considered to have suspected meningitis if they presented
with fever (>38.3 C) along with one of the following signs: neck
stiffness, bulging fontanelle (in children aged <12 months),
altered consciousness and irritability, or convulsions. Children
eligible for recruitment into the study underwent chest
radiography, blood specimen collection, and lumbar puncture,
as determined by the treating physician.
All chest radiographs were screened for substantial alveolar
consolidation by a physician at each sentinel site (reader 1) and
scanned using a VIDAR high-resolution digitizer for further
interpretation. The scanned radiographs were sent to two
independent radiologists trained in World Health Organization
(WHO) protocols (readers 2 and 3) (World Health Organization,
2001; O’Grady et al., 2010) for X-ray interpretation in a blinded
fashion. Radiographs with discordant end-points between reader 2
and 3 were interpreted by an additional senior radiologist, with
two out of three agreements considered the final diagnosis for
radiographically proven pneumonia. For quality assurance, every
fourth negative radiograph identified from each sentinel site was
sent to readers 2 and 3 for verification.
Lumbar puncture specimens of cerebrospinal fluid (CSF)
obtained from children with suspected meningitis were analyzed
for cell count; visibly cloudy specimens or those with a white blood
cell count >10  106/l were considered diagnostic of bacterial
meningitis.
All children with radiographically proven pneumonia or
bacterial meningitis were considered eligible for study enroll-
ment. Blood samples from children with radiographically proven
pneumonia and CSF samples from bacterial meningitis case
patients were sent to the Infectious Disease Research Laboratory
at Aga Khan University (AKU-IDRL) in Karachi at a controlled
temperature (2–8 C) for the detection of S. pneumoniae by lytA-
targeted real-time PCR (Maria da Gloria et al., 2007). A case met
the criteria for IPD if S. pneumoniae was detected in either blood or
CSF specimens on PCR. Serotype determination was done using
serial multiplex PCR. Details of laboratory methods for blood PCR
are provided elsewhere (Kabir et al., 2017). IPD cases were
classified as vaccine-type (VT-IPD) if the serotype matched those
present in the PCV10 composition (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F,
and 23F) or if they were from the same serogroups (e.g. 6A/B/C/D,
7A/F, 18A/B/C/F).
Children were excluded if they had been enrolled previously,
were not eligible to receive vaccines, resided outside the study
catchment area, or if parental consent was not obtained.
Five controls were enrolled from the same hospital for each case
of IPD, irrespective of serotype and vaccination status. Children
were excluded from enrollment as controls if they had signs of
suspected pneumonia, meningitis, or fever of unknown origin, if
they lived outside the catchment area, or if their parents did not
provide consent. Controls were matched to case patients by age,
district, and season. Controls were age-matched within 8 weeks of
case patient age for case patients aged <1 year and within 12 weeks
for case patients aged 1 year. Controls were randomly identified
from the inpatient wards and emergency rooms and enrollment
was completed within 2 months of enrollment of the respective
IPD case. In some instances, where an enrolled control was
vaccinated but did not have a clear vaccination history (i.e., lacked
a verifiable vaccination record), an additional control was enrolled.
All additional controls were included in the calculation of vaccine
effectiveness (VE).
A. Riaz et al. / International Journal of Infectious Diseases 80 (2019) 28–33 29
Downloaded for Anonymous User (n/a) at Aga Khan University Hospital from ClinicalKey.com by Elsevier on January 29, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
Data collection
Parents/caretakers of all enrolled children were interviewed in
person by trained research staff using a standardized question-
naire. Data were collected on demographic characteristics and
household information, including the number of people residing in
the household, index child’s exposure to smoke, treatment history
and outcome of disease for the current illness, and vaccination
history. Where available, vaccination cards were used to verify
vaccination history. These cards were reviewed by two indepen-
dent research staff in a blinded manner. In the case of discrepancy
between the two readers, vaccination status was verified with the
EPI center where the child was vaccinated, as identified by the
parents. When parents indicated that the child had not received
any vaccination, the oral history was used.
Sample size
The sample size was calculated using NCSS PASS v. 11 software
(NCSS, 2019) for a matched case–control study design. Initially the
sample size was calculated to assess VE against overall IPD. However,
it was recalculated in 2014 to detect a VE of 73% for VT-IPD with at
least three doses of PCV10 (Domingues et al., 2014). Using an alpha
error of 0.05, 80% power, 50% vaccine coverage for PCV10, and a
correlation coefficient for vaccination between matched cases and
controls of 0.20, it was estimated that 28 VT-IPD cases with five
matched controls for each case would be needed.
Data quality and statistical analysis
All case registration forms were double-entered using Visual
Foxpro v. 6.0 (Microsoft Corporation, USA). Enrollment logs (forcases
and controls) were reviewed on a weekly basis by the primary
investigator. Data were analyzed using Stata software version 12.0
(Hamilton, 2013). The Chi-square test and t-test were applied for the
comparison of characteristics between case patients and controls.
Standard analysis was conducted using logistic regression to
calculate the odds ratio (OR) of PCV10 vaccination versus no
vaccination in VT-IPD cases compared with controls (Pearce, 2016).
VE was calculated with the formula, VE = (1  OR)  100%. For VE
analysis, the vaccine dose was considered valid if received before
hospitalization. Confounders and risk factors were assessed by
including additional variables such as sex, age, wasting, stunting,
underweight, paternal education, large family size (5 family
members), exposure to cigarette smoke in the house, exposure to
cooking smoke, use of natural gas for cooking, at least one other
child <5 years of age in the house, and crowding (>2 people sleeping
in the same room as the child). Propensity scores for significant
confounders and risk factors including sex, age, and paternal
education, use of natural gas for cooking, crowding, cigarette
smoking, and exposure to smoke (p-values 0.25) were used for the
final adjusted multivariable model.
Results
A total 10124 children with suspected pneumonia and 2567
childrenwith suspected meningitis were screened at the sentinel sites
using the eligibility criteria. Of 6554 eligible children, 2530 (38.6%)
were identified as having suspected pneumoniabystudy physicians at
the sentinel sites and underwent chest radiography. Of these, 1426
(56.3%) were diagnosed with radiographically confirmed pneumonia
by radiologists at subsequent levels of X-ray interpretation.
Among 1726 eligible children with suspected meningitis, 213
(12.3%) were diagnosed with bacterial meningitis and their CSF
samples were submitted for PCR testing.
A total of 92 case patients with IPD were enrolled, including 63
cases of pneumococcal meningitis and 29 cases of pneumococcal
pneumonia (Figure 1). Among these, a serotype could be
determined for 60 (65.2%). Twenty-four (26%) were identified as
vaccine types (VT-IPD), as defined above. Thirty-six cases (39.1%)
were non-vaccine types (NVT) and 32 (34.7%) could not be typed
with the available panel of multiplex PCR reactions employed.
Table 1 provides the general characteristics of the 24 VT-IPD case
patients. The mean age of the VT-IPD case patients was 6.5 months;
Figure 1. Study profile.
Table 1
Characteristics of enrolled children with vaccine-serotype IPD.
Characteristics Case patients
(n = 24), n (%)
Age in months, mean  SD 6.5  4.1
Clinical syndrome
Pneumococcal meningitis 17 (70.8)
Pneumococcal pneumonia 7 (29.2)
Medical care
Admitted to hospital 24 (100)
Duration of hospitalization in days, mean  SD 9.3  6.7
Death (outcomes)
Overall 5 (20.8)
In cases of pneumonia 2 (40)
In cases of meningitis 3 (60)
IPD, invasive pneumococcal disease; SD, standard deviation.
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six of 24 were <14 weeks of age, too young to have been eligible for
three PCV10 doses. Seventeen (71%) had meningitis and seven
(29%) had pneumonia. The average duration of hospitalization for
these case patients was 9.3 days. Of the 24 VT-IPD case patients,
five died during their hospital stay.
Among the 24 cases of VT-IPD, seven (29%) were serotype 19F,
with 14 and 23F as other predominant serotypes. Furthermore, 21
out of 24 cases occurred in children who had not received even a
single dose of PCV10. Only one case each of serotypes 23F and 5
were identified: one in a child who had received two doses of
PCV10 and one in a child who had received a single dose; only one
child with serotype 1 disease had received all three doses of
PCV10 (Figure 2).
VE for PCV10 was calculated for the 24 VT-IPD cases along with
134 age-matched controls. Table 2 presents a comparison of the
demographic characteristics of enrolled case patients and controls.
There was no difference in mean age, nutritional status, family size,
or crowded living conditions between case patients and controls.
Statistically significant differences between case patients and
controls were found in sex, parental education, exposure to
cigarette smoke in the home, use of natural gas for cooking, and
vaccination status. While 44% of controls compared to 29% of case
patients had received at least a single dose of pentavalent vaccine
(comprising five vaccine antigens: diphtheria, pertussis, tetanus,
hepatitis B, and Haemophilus influenzae type B), this difference was
not statistically significant. The majority of both case patients
(87.5%) and controls (66.4%) had not received any doses of PCV10.
Table 3 provides unadjusted and adjusted VE against VT-IPD
with 95% confidence intervals (CI). Estimated VE against VT-IPD
was 72.7% (95% CI 7.2% to 92.6%) for at least one dose of PCV10
and 78.8% (95% CI 11.9% to 96.0%) for at least two doses. Only 4.2%
of case patients had received all three doses of PCV10, compared to
17.9% of controls, resulting in VE of 81.9% (95% CI 55.7% to 97.9%).
Point estimates of VE were lower for those receiving exactly two
doses of PCV10 (71.4%) and one dose of PCV10 (51.5%), compared to
no vaccination. Effectiveness against non-PCV10 serotypes was not
significantly different from zero for different vaccination statuses
(Table 3).
Figure 2. Vaccination status by serotype for vaccine serotype cases (n = 24).
Table 2
Comparison of characteristics of case patients and controls.a
Case patients
(n = 24), n (%)
Controls
(n = 134), n (%)
Sex, male 7 (29.2) 81 (60.5)
Age (months), mean  SD 6.5  4.1 7.1  4
Wasting (weight-to-height Z-score <2) 9 (39.1) 31 (26.7)
Stunting (height-to-age Z-score <2) 12 (52.2) 64 (58.2)
Underweight (weight-to-age Z-score <2) 14 (66.7) 72 (60)
Illiterate (paternal education) 18 (75) 55 (41)
Large family size (5 family members) 14 (58.3) 91 (67.9)
Person smoking cigarettes in the house 7 (29.2) 38 (28.4)
Exposure to cooking smoke (2 meters or closer to cooking smoke) 2 (8.3) 4 (3.0)
Use of natural gas for cooking 15 (62.5) 116 (86.6)
At least 1 other child <5 years old in the house 15 (62.5) 98 (73.1)
Crowding (>2 people sleeping in the same room as the child) 22 (91.7) 130 (97)
At least one dose of pentavalent vaccineb 7 (29.2) 59 (44)
Number of doses of PCV10
Zero doses 21 (87.5) 89 (66.4)
1 dose 1 (4.2) 12 (9.0)
2 doses 1 (4.2) 9 (6.7)
3 doses 1 (4.2) 24 (17.9)
1 dose 3 (12.5) 45 (33.6)
2 doses 2 (8.7) 33 (27.1)
SD, standard deviation; PCV10, 10-valent pneumococcal conjugate vaccine.
a p-Values for the comparison of proportions between the study groups were calculated using the Chi-square test; p-values to compare means across the study groups were
calculated using the unpaired t-test.
b Comprising five vaccine antigens: diphtheria, pertussis, tetanus, hepatitis B, and Haemophilus influenzae type B.
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Discussion
The study findings suggest that PCV10 is protective against IPD
(mainly pneumococcal meningitis) in the study population, for
disease caused by vaccine types among children in South Asia. The
study also showed that VE was associated with the number of
doses received, as the point estimate for VE increased with each
subsequent dose, from 51.5% among those receiving a single dose
to 81.9% among those receiving all three doses, a trend that has also
been identified in other studies (Domingues et al., 2014; Palmu
et al., 2013; Conklin et al., 2014). The study provides a useful insight
into VE and the distribution of vaccine serotypes in South Asia. The
estimated results of VE are encouraging and data from this study
could be helpful in studies performing a pooled analysis of PCV
effectiveness.
The confidence intervals for the VE estimates crossed the null
for all vaccination statuses examined, i.e., 1 dose, 2 doses, and
three doses PCV10. The wide confidence intervals can be attributed
to the small sample size and poor coverage of PCV10 within the
catchment population, where only 4.2% of case patients and 17.9%
of controls had received all three doses of PCV10. At the outset of
vaccine rollout, the EPI had planned to achieve 72% coverage of
PCV10 within 6 years of vaccine introduction (EPI, 2014). An
independent survey conducted during 2016 in three rural districts
of Sindh indicated the highest coverage for all three doses of PCV10
to be 38.5% (Anon, 2017). The sample size calculation for this study
employed an assumption of at least 50% coverage of PCV10 within
3 years of vaccine rollout. However, the required coverage levels
were not achieved within the study duration. This may have
affected the power of the study. In order to achieve the optimal
impact of PCV10 at the population level, vaccine coverage needs to
increase significantly through investments in vaccine promotion,
addressing vaccine hesitancy among the local population and
enhancing coverage.
An interesting feature of this study was the relatively small
proportion of VT-IPD out of the total IPD detected. Prior to the
introduction of the vaccine into the routine immunization program
in Pakistan, a hospital-based surveillance study from Sindh
indicated that 66.7% of all IPD cases among children aged less
than 5 years were PCV10 type serotypes (Shakoor et al., 2014). The
proportion of VT-IPD cases in this study was only 26%. This is likely
an indication of the altering bacteriological milieu with the
introduction of PCV10. With the level of coverage measured among
the controls in this study and in the independent surveys, the
proportion of IPD caused by vaccine serotypes would be expected
to drop, both because of direct protection among children who
have received PCV10 doses and the decreased transmission of
vaccine serotype strains from vaccinated children to unvaccinated
children (indirect or herd effects). At these coverage levels,
however, indirect protection will probably not be as good as
expected with higher coverage (Loughlin et al., 2014). The most
common PCV10 serotype found in this study was 19F, which
accounted for a higher proportion of the isolates than was found in
a previous study in the same setting (Shakoor et al., 2014).
Whether this represents a relative shift because other vaccines
serotypes are less common after vaccine introduction is unknown.
In addition to the lack of coverage with PCV10, other factors
found to be associated with IPD included parental illiteracy and
natural gas used for cooking. The odds of having an illiterate parent
were significantly higher among case patients than among
controls, suggesting that parental education may play a role in
knowledge about vaccines and other health services or in the
family’s economic status and overall well-being. The use of natural
gas for cooking was more prevalent for control patients than for
case patients; while the findings suggest that there may be a direct
linkage between exposure to indoor smoke and the subsequent
development of IPD, data to control for confounding factors are
insufficient.
In conclusion, the VE point estimates for PCV10 were high and
increased progressively with increasing doses of PCV10. The VE
estimates did not reach statistical significance in this study, but
this may be due to the low power, as explained above. The study
results suggest that the introduction of PCV10 with adequate
coverage is likely to decrease the IPD burden among children less
than 5 years of age in Pakistan.
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Table 3
Unadjusted and adjusted PCV10 effectiveness against vaccine-type and non-vaccine type invasive pneumococcal disease outcomes in case patients and controls.
Vaccination status Cases
(n = 24), n (%)
Controls





VE for PCV10 serotypes
Zero PCV doses 21 (87.5) 89 (66.4) Reference Reference
1 dose 1 (4.2) 12 (9) 64.7 (186.9 to 95.7) 51.5 (343.7 to 94.7)
2 doses 1 (4.2) 9 (6.7) 52.9 (292.3 to 94.3) 71.4 (227.6 to 97.5)
3 doses 1 (4.2) 24 (17.9) 82.3 (38.0 to 97.7) 81.9 (55.7 to 97.9)
1 dose 3 (12.5) 45 (33.6) 71.7 (0.2 to 92.0) 72.7 (7.2 to 93.1)
2 doses 2 (8.7) 33 (27.1) 74.3 (15.6 to 94.3) 78.8 (11.9 to 96.0)
Vaccination status Cases
(n = 67), n (%)
Controls





VE for non-PCV10 serotypes
Zero PCV doses 38 (56.7) 203 (58.8) Reference Reference
1 dose 29 (43.3) 142 (41.2) 9.1 (85.1 to 35.7) 44.9 (154.6 to 17.6)
2 doses 23 (37.7) 115 (36.2) 6.8 (88.2 to 39.3) 54.1 (183.7 to 16.3)
PCV10, 10-valent pneumococcal conjugate vaccine; VE, vaccine effectiveness; CI, confidence interval.
a Adjusted for sex, age, paternal education, use of natural gas for cooking, crowding and exposure to smoke based on propensity scores, VE = (1  OR)  100%.
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